A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 01 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BPX 201 (Primary) ; Rivogenlecleucel (Primary) ; Cyclophosphamide
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Registrational
Acronyms THRIVE
Sponsors Bellicum Pharmaceuticals

Most Recent Events

14 Jan 2020 Status changed from recruiting to suspended.
24 Oct 2019 Planned End Date changed from 1 Jul 2024 to 1 Jul 2038.
14 Mar 2019 Planned End Date changed from 1 Jun 2024 to 1 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight